$1bn Deal Boosts Takeda, Arrowhead’s Liver Disease And RNAi Ambitions
Follows Promising Recent Clinical Data
Executive Summary
Takeda's global deal for one of US RNAi specialist's lead assets follows recent promising clinical results in serious disorder with no current therapeutic options.
You may also be interested in...
Keeping Track: Breakthroughs Of Summer Break Ground In Psychiatry, Cancer (Especially Nasopharygeal Cancer) And Vaccines
US FDA’s marquee expedited review program added 15 new breakthrough therapy designations between June and August.
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.